Karyopharm Therapeutics Inc. (KPTI) Discusses Top Line Results From Phase III SENTRY Trial in Myelofibrosis - Slideshow

Karyopharm Therapeutics presented top-line Phase III SENTRY trial results for its myelofibrosis treatment, evaluating the oral drug selinexor in patients resistant to or intolerant of JAK inhibitors. The trial met its primary endpoint, demonstrating statistically significant spleen volume reduction at 24 weeks compared to placebo, with detailed efficacy data pending full analysis. Safety profiles were consistent with prior studies, though adverse events—including thrombocytopenia and nausea—remained notable, aligning with selinexor’s known tolerability challenges in hematologic malignancies. Company leadership emphasized the potential for selinexor to address unmet needs in myelofibrosis, a rare bone marrow cancer with limited therapeutic options after JAK inhibitor failure. Investor focus now shifts to regulatory submissions, with Karyopharm planning to discuss findings with the FDA in mid-2026 to explore accelerated approval pathways.